| Accession |
PRJCA026598 |
| Title |
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with ER+, HER2- Advanced Breast Cancer |
| Relevance |
Medical |
| Data types |
Genome sequencing
Genome-targeted sequencing
|
| Organisms |
Homo sapiens
|
| Description |
Protocol Title: EMBER-3, A Phase 3, Randomized, Open-Label, Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy. Protocol Primary Objectives: 1. To compare the PFS of imlunestrant to the standard comparator of investigator's Choice Endocrine Therapy of either fulvestrant or exemestane in the ITT population; 2. To compare the PFS of imlunestrant to the standard comparator of investigator's Choice Endocrine Therapy of either fulvestrant or exemestane in the ESR1- mutation detected population; 3.To compare the PFS of imlunestrant plus abemaciclib to imlunestrant in the ITT population |
| Sample scope |
Multiisolate |
| Release date |
2024-05-29 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Eli Lilly and Company
|
|
2022LP00914/2022LP00915
|
|
|
|
| Submitter |
Yujie
Hu (hu_yujie@Lilly.com)
|
| Organization |
Eli Lilly and Company |
| Submission date |
2024-05-29 |
